All Updates

All Updates

icon
Filter
Funding
Trobix Bio raises USD 3 million in Series A extension
Precision Medicine
Mar 30, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Mar 30, 2023

Trobix Bio raises USD 3 million in Series A extension

Funding

  • Israeli-based biotech company Trobix Bio has raised USD 3 million in a Series A extension round led by Chartered Group, a global private investment group. This brings the total funds raised to USD 6 million. 

  • The funds will be used to further develop the company's products, including TBX201, an orally available capsule designed to reduce the incidence and severity of severe diarrhea caused by irinotecan, and TBX301, an orally available capsule designed to reduce the incidence and severity of colitis in patients receiving immune checkpoint inhibitors. The funds will also be used to advance the TBX platform technology, which uses computational, synthetic, and synthetic biology technologies to engineer phages as medicines that reprogram targeted microbiome bacteria.

  • Trobix Bio is a biotech company that focuses on utilizing CRISPR, phage (viruses that infect bacteria), and synthetic biology technologies to develop precision microbiome oncology therapeutics. Trobix Bio operates a B2B business model as it partners with pharmaceutical companies to integrate its technology into their oncology treatments.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.